Drug Profile
Zilucoplan - UCB
Alternative Names: RA 101495; RA101495 SC; ZILBRYSQ; ZilbrysqLatest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Ra Pharmaceuticals
- Developer Ra Pharmaceuticals; UCB
- Class Antianaemics; Antivirals; Cyclic peptides; Lactams; Macrocyclic compounds; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myasthenia gravis
- Phase III COVID 2019 infections
- Phase II/III Amyotrophic lateral sclerosis
- Discontinued Haemolytic uraemic syndrome; Immune-mediated necrotising myopathy; Lupus nephritis; Paroxysmal nocturnal haemoglobinuria; Respiratory insufficiency; Unspecified
Most Recent Events
- 03 Jan 2024 Launched for Myasthenia gravis in USA (SC)
- 04 Dec 2023 UCB intends to launch zilucoplan for Myasthenia gravis (Adjunctive treatment) in European Union in the first quarter of 2024
- 04 Dec 2023 UCB anticipates response from the TGA of Australia for the approval of zilucoplan for Myasthenia gravis between H2 2023 and H2 2024